The role of COVID‐19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical‐year medical students in Indonesia

The role of COVID‐19 survivor status and gender towards neutralizing antibody titers 1, 2, 3 months after Sinovac vaccine administration on clinical‐year medical students in Indonesia

Background: Sinovac was the first vaccine used in Indonesia against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, data regarding the effects of certain variables such as clinical demographics on antibody levels in individuals vaccinated with Sinovac are scarce. This study ai...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rivaldo Steven Heriyanto, Andree Kurniawan, Felix Wijovi, Devina Adella Halim, Claudia Jodhinata, Elizabeth Marcella, Billy Susanto, Johan Wibowo, Michele Indrawan, Nadia Khoirunnisa Heryadi, Michelle Imanuelly, Jonathan Juniard Anurantha, Timotius Ivan Hariyanto, Chintya Marcellin, Terry Devita Sinaga, Saraswati Anindita Rizki, Novia Sieto, Jeremia Immanuel Siregar, Nata Pratama Hardjo Lugito
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
COVID-19
antibody titers
Sinovac vaccine
COVID-19 vaccine
Infectious and parasitic diseases
RC109-216
Acceso en línea:https://doaj.org/article/2d956e8e294e4a3280b6e0917a7395ac
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/2d956e8e294e4a3280b6e0917a7395ac

Ejemplares similares